Product image of Myalepta (Metreleptin) supplied by GNH India

Myalepta

Active Ingredient:
Metreleptin
Origin:
EU

Myalepta (Metreleptin)

Metreleptin, the active ingredient in Myalepta, is a leptin analog presented as a subcutaneous injectable for subcutaneous use. It replaces deficient endogenous leptin and is indicated for the treatment of generalized lipodystrophy, partial lipodystrophy, and leptin deficiency in affected patients.

GNH India supplies Myalepta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, specialty clinics and pharmacies worldwide, adhering to stringent quality standards and providing reliable cold‑chain logistics for biologic products. Our team coordinates regulatory documentation and offers post‑delivery support to ensure uninterrupted patient care.

Manufacturer / TM Owner

Chiesi Farmaceutici S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myalepta (metreleptin) is used to address leptin deficiency and related metabolic disturbances in lipodystrophy syndromes.

  • Generalized lipodystrophy: improves metabolic control by lowering triglycerides, reducing hepatic fat accumulation, and enhancing insulin sensitivity.
  • Partial lipodystrophy: helps normalize serum lipid concentrations, improve glycemic control, and mitigate ectopic fat deposition.
  • Leptin deficiency: restores physiologic leptin signaling, aiding regulation of appetite, energy expenditure, and metabolic homeostasis.

How It Works

  • Metreleptin is a recombinant human leptin analog that binds to the leptin receptor (LEPR) in the hypothalamus and peripheral tissues. Activation of LEPR triggers the JAK‑STAT signaling cascade, leading to transcription of genes that suppress appetite, increase energy expenditure, and improve insulin sensitivity, thereby correcting the metabolic abnormalities associated with leptin deficiency. It also modulates neuroendocrine pathways that influence glucose and lipid metabolism.

Side Effects

Metreleptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site reactions: redness, swelling, or pain at the administration site.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal discomfort.
  • Upper respiratory tract infection: symptoms such as cough or sore throat.
  • Fatigue: feeling of tiredness or lack of energy.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Development of anti‑leptin antibodies: may reduce efficacy or cause hypersensitivity.
  • Severe hypersensitivity reactions: including anaphylaxis or angioedema.
  • Hepatic complications: worsening liver function or hepatitis.
  • Malignancy reports: rare cases of lymphoma observed in clinical studies.

Precautions & Warnings

When prescribing metreleptin, clinicians should consider several precautionary measures to ensure patient safety.

  • Monitoring antibodies: assess for anti‑leptin antibodies that may diminish response.
  • Liver function: evaluate hepatic enzymes regularly due to potential liver effects.
  • Hypoglycemia risk: monitor glucose levels, especially in patients on insulin or hypoglycemic agents.
  • Immunogenicity: be vigilant for signs of hypersensitivity or allergic reactions.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Metreleptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Immunosuppressants: may increase risk of antibody formation and reduce therapeutic effect.
  • Live vaccines: concurrent use can blunt vaccine response and increase infection risk.

Moderate Interactions (Monitor Closely)

  • Insulin or oral hypoglycemics: metreleptin may enhance glucose‑lowering effect, requiring dose adjustment.
  • Lipid‑lowering agents: monitor lipid profile as changes may occur.
  • Hormonal therapies: potential alterations in hormone levels may need observation.

Frequently Asked Questions

Myalepta contains metreleptin, a recombinant leptin analog indicated for the treatment of generalized lipodystrophy, partial lipodystrophy, and congenital leptin deficiency. It helps correct metabolic abnormalities such as severe hypertriglyceridaemia, insulin resistance, and hepatic steatosis in patients with deficient endogenous leptin.

Metreleptin replaces the missing natural hormone leptin by binding to leptin receptors in the hypothalamus and peripheral tissues. This activates the JAK‑STAT pathway, leading to reduced appetite, increased energy expenditure, and improved insulin sensitivity, thereby restoring metabolic balance.

Dosing of Myalepta is individualized. The prescribing clinician determines the appropriate amount based on the patient’s weight, severity of leptin deficiency, and clinical response. No fixed regimen is provided in public information.

Safety data for metreleptin in pregnancy and lactation are limited. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed by a specialist familiar with the condition.

To request Myalepta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Myalepta is the only approved recombinant leptin therapy that directly addresses leptin deficiency. Alternative approaches focus on metabolic control through diet, insulin, and lipid‑lowering agents, but they do not replace the missing hormone. Consequently, metreleptin offers a disease‑specific mechanism that can achieve metabolic improvements not attainable with standard therapies alone.

Myalepta must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Myalepta is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained patient following aseptic technique.

Serious risks include the development of anti‑leptin antibodies that can diminish therapeutic effect, severe hypersensitivity reactions such as anaphylaxis or angioedema, and potential hepatic complications. Rare cases of lymphoma have also been reported, so patients should be monitored closely for any unusual symptoms.

Myalepta is contraindicated in patients with known hypersensitivity to metreleptin or any excipients in the formulation. It should also be avoided in individuals receiving live vaccines without appropriate timing, and in patients where the risk‑benefit assessment does not support use, such as those with uncontrolled severe infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metreleptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT